drugset / Trial / NCT00369031
Safety Study Of Nasal HIV Vaccine Adjuvanted With LTK63
Phase 1
Terminated
31 enrolled
St George's, University of London
European Union · collabNovartis Vaccines · collabRichmond Pharmacology Limited · collab
Non-randomizedParallel-groupOpen-labelPrevention
Summary
The purpose of this study is to determine whether an HIV vaccine given as three nasal immunisations with a protein from HIV virus mixed with a toxoid adjuvant, followed by two intramuscular immunisations with the same protein mixed with a liquid adjuvant, causes untoward adverse reactions when administered to healthy adult volunteers. An initial evaluation of immune responses to the vaccine will also be undertaken.
Timeline
- Start
- 2006-09
- Primary completion
- 2007-11
- Completion
- 2008-03
Outcome
Outcome not reported
Stopped: “Safety issues”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Human Immunodeficiency Virus glycoprotein 140 | Unknown | — | Intranasal |
| Comparator | LTK63 | Unknown | — | Intranasal |